Healthcare ❯Pharmaceuticals ❯Drug Approval ❯Cardiovascular Health
The Danish pharmaceutical giant's experimental drug, amycretin, demonstrates significant weight loss in early trials, potentially outperforming its predecessors, Wegovy and Ozempic.
